Breakthrough oral CDK9 inhibitor advances care for patients with recurrent high-grade gliomas harboring IDH1/2 mutationsFOR IMMEDIATE RELEASESan Mateo, CA and Bethesda, MD — November 26, 2025 — Cothera Bioscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zotiraciclib (ZTR/TG02) for the treatment...
Cothera Bioscience Announces FDA Fast Track Designation for Clinical Program PC-002
San Francisco, California, October 14, 2024 — Cothera Bioscience, a leading biotech innovator advancing clinical stage therapeutics for previously undruggable oncology targets with high unmet medical needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program PC-002, a...
Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma
San Francisco December 7, 2023 – Cothera Bioscience, a clinical stage biotech company developing therapeutics for previously undruggable oncology targets with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PC-002, a first-in-class deubiquitinase (DUB) inhibitor that induces myc...